TICKERNOMICS Sign up
Last Update: 2024-12-27 15:23:36
ACADIA PHARMACEUTICALS INC ( ACAD ) https://www.acadia-pharm.com
17.37USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-44.66%
ACAD
SPY
32.66%
-29.59%
ACAD
SPY
108.59%
-60.50%
ACAD
SPY
302.52%
-45.19%
ACAD
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2886.51
2370.55
0.75
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
22.46
3.11
5.00
7.87
0.00
21.99
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
12.64
92.47
11.37
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.2704
42.54
22.77
0.53
Other Earnings and Cash Flow Stats:
ACADIA PHARMACEUTICALS INC ( ACAD ) Net Income TTM ($MM) is 128.51
ACADIA PHARMACEUTICALS INC ( ACAD ) Operating Income TTM ($MM) is 112.23
ACADIA PHARMACEUTICALS INC ( ACAD ) Owners' Earnings Annual ($MM) is 0.00
ACADIA PHARMACEUTICALS INC ( ACAD ) Current Price to Owners' Earnings ratio is 0.00
ACADIA PHARMACEUTICALS INC ( ACAD ) EBITDA TTM ($MM) is 117.36
ACADIA PHARMACEUTICALS INC ( ACAD ) EBITDA Margin is 11.37%
Capital Allocation:
ACADIA PHARMACEUTICALS INC ( ACAD ) has paid 0.00 dividends per share and bought back -1.944 million shares in the past 12 months
ACADIA PHARMACEUTICALS INC ( ACAD ) has reduced its debt by 7.764 million USD in the last 12 months
Capital Structure:
ACADIA PHARMACEUTICALS INC ( ACAD ) Interest-bearing Debt ($MM) as of last quarter is 49
ACADIA PHARMACEUTICALS INC ( ACAD ) Annual Working Capital Investments ($MM) are -138
ACADIA PHARMACEUTICALS INC ( ACAD ) Book Value ($MM) as of last quarter is 577
ACADIA PHARMACEUTICALS INC ( ACAD ) Debt/Capital as of last quarter is 8%
Other Balance Sheet Stats:
ACADIA PHARMACEUTICALS INC ( ACAD ) has 155 million in cash on hand as of last quarter
ACADIA PHARMACEUTICALS INC ( ACAD ) has 343 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ACADIA PHARMACEUTICALS INC ( ACAD ) has 166 common shares outstanding as of last quarter
ACADIA PHARMACEUTICALS INC ( ACAD ) has 0 million USD of preferred stock value
Academic Scores:
ACADIA PHARMACEUTICALS INC ( ACAD ) Altman Z-Score is 2.85 as of last quarter
ACADIA PHARMACEUTICALS INC ( ACAD ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
ACADIA PHARMACEUTICALS INC ( ACAD ) largest shareholder is owning shares at 0.00 ($MM) value
Teehan Brendan(an insider) Sold 10329 shares of ACADIA PHARMACEUTICALS INC ( ACAD ) for the amount of $173630.49 on 2024-11-19
0.53% of ACADIA PHARMACEUTICALS INC ( ACAD ) is held by insiders, and 99.84% is held by institutions
ACADIA PHARMACEUTICALS INC ( ACAD ) went public on 2004-05-27
Other ACADIA PHARMACEUTICALS INC ( ACAD ) financial metrics:
FCF:202.61
Unlevered Free Cash Flow:0.00
EPS:0.79
Operating Margin:12.64
Gross Profit Margin:92.47
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:22.71
Beta:0.53
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ACADIA PHARMACEUTICALS INC ( ACAD ) :
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.